Search results for " World Health Organization"

showing 10 items of 17 documents

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systema…

2020

Publisher's version (útgefin grein)

Index (economics)Servicios de SaludSUSTAINABLE DEVELOPMENT GOALS030204 cardiovascular system & hematologyuniversal health coverage; sustaibale develpment goal; global burden of disease; performance;universal health coveragesystematic analysisGlobal Burden of Disease0302 clinical medicineUniversal Health InsuranceRA042111. SustainabilityPer capitaMedical economicsDisease030212 general & internal medicine10. No inequality11 Medical and Health Scienceseffective coverage of health servicesGBD 2019 Universal Health Coverage Collaboratorseducation.field_of_studyPublic healthMedical careSjúkdómar4. Education1. No povertyHealth coveragePublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineHälsovetenskaper3142 Public health care science environmental and occupational healthHealth services3. Good healthGlobal burden of diseaseGlobal Burden of Disease; Health Expenditures; Humans; Universal Health Insurance; World Health OrganizationPurchasing power parityScale (social sciences)/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingLýðheilsauniversal health coveragCANCER SURVIVALACCESSperformanceHumanHeilsuhagfræðimedicine.medical_specialtyHealth coverage GBDGBDUniversal healthGBD 2019Population2019Health expenditures3122 CancersPopulation healthWorld Health Organization03 medical and health sciencesHealth systemsHeilbrigðisvísindiSDG 3 - Good Health and Well-beingGeneral & Internal MedicineDevelopment economicsHealth SciencesmedicineHeilbrigðisstefnasustaibale develpment goalAlþjóðaheilbrigðisstofnuninHumansQUALITYGlobal Burden of Disease StudyeducationPROGRESSDisease burdenPublic healthHealth services accessibilityCAREHeilbrigðisþjónusta//purl.org/pe-repo/ocde/ford#3.02.00 [https]Health ExpenditureFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineMorbilityAdministración de los Servicios de SaludMedical policyBusinessHealth ExpendituresHeilbrigðiskerfi
researchProduct

La qualità dell’aria indoor: una priorità ambientale e sanitaria

2009

Tobacco Smoke Pollution; Multicenter Studies as Topic; Animals; Questionnaires; Air Pollution Indoor; Humans; Air Pollutants; Asthma; Child; Europe; Child Welfare; Italy; Life Style; Environmental Monitoring; World Health Organization; Respiratory Tract Diseases; Allergens; Cats; Dogs; Urban PopulationUrban PopulationAnimalQuestionnaireAllergenChild WelfareCatWorld Health OrganizationAsthmaEuropeItalyAir PollutantAir Pollution IndoorDogMulticenter Studies as TopicTobacco Smoke PollutionChildLife StyleRespiratory Tract DiseaseHumanEnvironmental Monitoring
researchProduct

Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020

2020

8 páginas, 3 figuras

Infecções Respiratórias0301 basic medicineMESH: Coronavirus InfectionsEpidemiology[SDV]Life Sciences [q-bio]Distribution (economics)WastewaterMESH: Base SequenceSevere Acute Respiratory SyndromeMESH: World Health OrganizationPandemicMESH: CoronavirusMESH: COVID-19SequencingViralCladeNomenclatureGenomebiologyNomenclatureCOVID-19; Europe; NGS; SARS-CoV-2; WGS; nomenclature; sequencing; Base Sequence; Betacoronavirus; COVID-19; Coronavirus; Coronavirus Infections; Europe; Genome Viral; Humans; Phylogeography; Pneumonia Viral; RNA Viral; RNA-Dependent RNA Polymerase; SARS-CoV-2; Severe Acute Respiratory Syndrome; Spatio-Temporal Analysis; World Health Organization; PandemicsC500sequencingEuropean region3. Good healthEuropePhylogeographyGeographyMESH: PhylogeographyMESH: RNA-Dependent RNA PolymeraseMESH: RNA ViralNGSMESH: BetacoronavirusRNA ViralSpatio-Temporal AnalysinomenclatureMESH: Genome ViralCoronavirus InfectionsCartographyHumanBioquímicaMESH: PandemicsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronaviruPneumonia Viral030106 microbiologyGenome ViralWorld Health OrganizationCOVID-19 ; Europe ; NGS ; SARS-CoV-2 ; WGS ; nomenclature ; sequencing03 medical and health sciencesBetacoronavirusMESH: Spatio-Temporal AnalysisSpatio-Temporal AnalysisMESH: Severe Acute Respiratory SyndromeVirologyHumansMESH: SARS-CoV-2PandemicsWhole genome sequencingMESH: HumansWhole Genome SequencingBetacoronaviruBase SequenceCoronavirus Infectionbusiness.industrySARS-CoV-2Public Health Environmental and Occupational HealthCOVID-19Pneumoniabiology.organism_classificationRNA-Dependent RNA PolymeraseB900Coronavirus030104 developmental biologyMESH: Pneumonia ViralRNASARS_CoV-23111 BiomedicineMESH: EuropeHuman medicinebusinessBetacoronavirusWGSEurosurveillance
researchProduct

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

2018

Abstract Background & Aims Advances in direct‐acting antiviral treatment of HCV have reinvigorated public health initiatives aimed at identifying affected individuals. We evaluated the possible impact of only diagnosed and linked‐to‐care individuals on overall HCV burden estimates and identified a possible strategy to achieve the WHO targets by 2030. Methods Using a modelling approach grounded in Italian real‐life data of diagnosed and treated patients, different linkage‐to‐care scenarios were built to evaluate potential strategies in achieving the HCV elimination goals. Results Under the 40% linked‐to‐care scenario, viraemic burden would decline (60%); however, eligible patients to treat w…

HCV; WHO; chronic infection; linkage to careLiver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularSustained Virologic ResponseViral HepatitisSettore MED/12 - GASTROENTEROLOGIAWorld Health OrganizationAntiviral AgentsNO03 medical and health sciencesLiver diseaseWHO0302 clinical medicinePharmacotherapyCost of IllnessCause of DeathHealth caremedicineHumans030212 general & internal medicineViremiachronic infection HCV linkage to care WHODisease EradicationMortalityIntensive care medicineCause of deathlinkage to carechronic infection; HCV; linkage to care; WHODisease EradicationHepatologybusiness.industryPublic healthCarcinomaLiver NeoplasmsHepatocellularHepatitis Cmedicine.diseasechronic infectionHepatitis CMarkov Chainschronic infection; HCV; linkage to care; WHO; Antiviral Agents; Carcinoma Hepatocellular; Cost of Illness; Disease Eradication; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Markov Chains; Mortality; Sustained Virologic Response; Viremia; World Health Organization; Cause of DeathItalychronic infection;HCV;linkage to care;WHOHCVchronic infection; HCV; linkage to care; WHO; Hepatology030211 gastroenterology & hepatologybusinessViral hepatitis
researchProduct

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

2014

International audience; The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patien…

AgingSettore MED/10 - Malattie dell'Apparato RespiratorioInternational CooperationRespiratory SystemMedically Underserved AreaComorbidityDiseaseEarly interventionMedical and Health Sciences[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractPulmonary Disease Chronic Obstructive0302 clinical medicineDisease controlRisk FactorsChronic obstructive lung diseaseHealth care030212 general & internal medicineRhinitimedia_commonRhinitisEnvironmental exposureChild health care3. Good healthALLERGIC RHINITISEuropeCHRONIC RESPIRATORY-DISEASESPERFORMANCE PROGRAMAction planSIMULATIONAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease; Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health OrganizationSMOKINGHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveChronic respiratory tract diseaseDecision MakingGuidelines as TopicDIAGNOSISWorld Health OrganizationOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease03 medical and health sciencesQuality of life (healthcare)EUROPEAN-UNIONmedicineMANAGEMENTmedia_common.cataloged_instanceHumansEuropean UnionEuropean unionIntensive care medicinebusiness.industryPublic healthRisk Factorta3121Respiration DisorderEnvironmental exposureRespiration DisordersAsthmaIntegrated care030228 respiratory systemPhysical therapyQuality of LifeClinical MedicineAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health Organizationbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologySEVERE ASTHMA
researchProduct

Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

2020

Abstract Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. Methods MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. Results We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group,…

Coronavirus COVID-19 Pneumonia SARS-CoV-2 TocilizumabGCA Giant cell arteritispJIA Pediatric juvenile idiopathic arthritislaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicine030212 general & internal medicineClinical efficacyCPAP Continuous positive airway pressureCOVID-19 Coronavirus disease 2019IDSA Infectious Diseases Society of AmericaRA Rheumatoid arthritisTocilizumabIMV Invasive mechanical ventilationsJIA Juvenile idiopathic arthritisAIFA Agenzia Italiana del FarmacoPulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINEAntibodies Monoclonal HumanizedNIH U.S. National Institutes of HealthArticleWHO World Health OrganizationSIMIT Italian Society of Infectious and Tropical disease03 medical and health sciencesTocilizumabARDS Acute respiratory distress syndromeAnimalsHumansIn patientIntensive care medicineTocilizumab ; COVID-19 ; Pneumonia ; SARS-CoV-2 ; Coronaviruslcsh:RC705-779business.industryCRS CAR-T cell-induced cytokine release syndromeInterleukin-6SARS-CoV-2NIV Noninvasive mechanical ventilationTNF Tumor necrosis factorCOVID-19Pneumonialcsh:Diseases of the respiratory systemCOVID-19 Drug TreatmentClinical trialCoronavirus030228 respiratory systemchemistrybusinessICTRP International Clinical Trials Registry PlatformPulmonology
researchProduct

Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis.

2020

Abstract Background Throughout the 5000-year history of China, more than 300 epidemics were recorded. Traditional Chinese herbal medicine (TCM) has been used effectively to combat each of these epidemics’ infections, and saved many lives. To date, there are hundreds of herbal TCM formulae developed for the purpose of prevention and treatment during epidemic infections. When COVID-19 ravaged the Wuhan district in China in early January 2020, without a deep understanding about the nature of COVID-19, patients admitted to the TCM Hospital in Wuhan were immediately treated with TCM and reported later with >90% efficacy. Approach We conducted conduct a systematic survey of various TCM herbal pre…

PTGS2 Prostaglandin-endoperoxide synthase 2BattleAIV avian influenza virusCoV coronavirusPharmaceutical ScienceiNOS nitric oxide synthaseViral infection0302 clinical medicinePA patchouli alcoholSARS Severe Acute Respiratory SyndromeSMD Sheganmahuang decoctionDrug DiscoveryPandemicIL InterleukinMedicine Chinese TraditionalALI acute lung injuriesmedia_commonCOVID-19 coronavirus disease 2019MXSG Ma xing shi gan decoction0303 health sciencesTNF tumor necrosis factorClinical Trials as TopicCCL2 CC chemokine ligand 2FM1 FM1 coronavirusICU intensive care unitc-AMP cyclic adenosine phosphateHIV human immunodeficiency virus030220 oncology & carcinogenesisCOX-2 cyclooxygenase-2Molecular MedicineHerbal preparationsMedicinal herbsAbbreviations: ACE2 angiotensin-converting enzyme IITCM traditional Chinese medicineHSV-1 herpes simplex virus 1CASP3 caspase 3medicine.medical_specialtyChinaCoronavirus disease 2019 (COVID-19)Systematic surveymedia_common.quotation_subjectJEV Japanese encephalitis virusNF-κB nuclear factor kappa B cellsAntiviral AgentsArticleWHO World Health Organization03 medical and health sciencesIEC-6 rat intestinal epithelial cell line 6SOD superoxide dismutaseCDC Center for Disease Control and PreventionmedicineAVP arginine vasopressinPGE2 prostaglandin E2HumansIntensive care medicineLH Lianhuaqingwen capsule030304 developmental biologyPharmacologyMedicinal herbMDA malondialdehydeGCGJ Gancao ganjiang decoctionNO nitric oxidePlants Medicinalbusiness.industrySARS-CoV-2COVID-19CXCL C-X-C- motif chemokineMDCK Madin-Darby Canine Kidney cellsTLR-4 Toll-like receptor-4COVID-19 Drug TreatmentComplementary and alternative medicineViral infectionLPS lipopolysaccharidesRSV respiratory syncytial virusQFPD Qingfeipaidu decoctionbusinessLung congestionECMO extracorporeal membrane oxygenationMAPK mitogen-activated protein kinasePhytotherapyDrugs Chinese HerbalPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.

2019

Glioblastoma (GBM) is the most common malignant primary tumor of the central nervous system. With no effective therapy, the prognosis for patients is terrible poor. It is highly heterogeneous and EGFR amplification is its most frequent molecular alteration. In this light, we aimed to examine the genetic heterogeneity of GBM and to correlate it with the clinical characteristics of the patients. For that purpose, we analyzed the status of EGFR and the somatic copy number alterations (CNAs) of a set of tumor suppressor genes and oncogenes. Thus, we found GBMs with high level of EGFR amplification, low level and with no EGFR amplification. Highly amplified tumors showed histological features of…

0301 basic medicineMaleCancer ResearchBiopsyL-amp GB EGFR-low amplified glioblastomamedicine.disease_causewt wildtypeMYBPC3 myosin-binding protein C0302 clinical medicineHIC1 hypermethylated in cancer 1Gene duplicationIn Situ Hybridization FluorescenceIDH2 isocitrate dehydrogenase 2MutationRB-pat RB signaling pathwayEGFRvIII epidermal growth factor receptor variant number IIIPAH phenylalanine hydroxylaseGBM glioblastoma IDH-wildtype (glioblastoma multiforme primary glioblastoma).ANOVA ANalysis Of VArianceN-amp GB EGFR-no amplified glioblastomaMiddle AgedCDKN2A cyclin-dependent kinase inhibitor 2Alcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisPrimary tumorImmunohistochemistryH-amp GB EGFR-high amplified glioblastomaErbB ReceptorsTKR-pat tyrosine-kinase receptors signaling pathway030220 oncology & carcinogenesisDisease ProgressionCDK6 cyclin-dependent kinase 6CDH1 Cadherin 1FemaleCREM cAMP response element modulatorIHC immunohistochemistryAdultOriginal articleDNA Copy Number VariationsCDKN1B cyclin-dependent kinase inhibitor 1BBiologyRARB retinoic acid receptor betaCNS central nervous systemlcsh:RC254-282IDH1 isocitrate dehydrogenase 1BCL2 B-cell cll/ lymphoma 2CNAs copy number algerationsWHO World Health Organization03 medical and health sciencesYoung Adultp53-pat p53 signaling pathwaymedicineBiomarkers TumorTMA tissue microarrayPTENHumansProtein kinase BPI3K/AKT/mTOR pathwaySurvival analysisAgedGenetic heterogeneityGene AmplificationGFAP glial fibrillary acidic proteinMLPA multiplex ligation-dependent probe amplificationmedicine.diseaseFISH fluorescence in situ hibridizationSurvival AnalysisCDKN2B cyclin-dependent kinase inhibitor 2BPTEN phosphatase and tensin homologEGFR epidermal growth factor receptorCNV-load load of copy number variations030104 developmental biologyMutationPARK2 parkinCancer researchbiology.proteinTCGA The Cancer Genome AtlasLARGE1 acetylglucosaminyltransferase-like protein 1GlioblastomaCHD7 Chromodomain Helicase DNA Binding Protein 7DAPI 4′6-diamidino-2-phenylindoleNeoplasia (New York, N.Y.)
researchProduct

Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases.

2021

Patients with pre-existing respiratory diseases in the setting of COVID-19 may have a greater risk of severe complications and even death.A retrospective, multicenter, cohort study with 5847 COVID-19 patients admitted to hospitals. Patients were separated in two groups, with/without previous lung disease. Evaluation of factors associated with survival and secondary composite end-point such as ICU admission and respiratory support, were explored.1,271 patients (22%) had a previous lung disease, mostly COPD. All-cause mortality occurred in 376 patients with lung disease (29.5%) and in 819 patients without (17.9%) (Previous lung disease is a risk factor for mortality in patients with COVID-19.…

HOPE-COVID-19 Health Outcome Predictive Evaluation for COVID-19Respiratory diseasesOriginal30-Day mortalityenfermedades respiratoriasACE2 angiotensin converting enzyme IIlaw.invention0302 clinical medicineCQ/HCQ chloroquine/hydroxychloroquinelawCOPDrespiratory diseasesPrognosisICU intensive care unitIntensive care unitSTROBE strengthening the reporting of observational studies in epidemiologypronósticomedicine.anatomical_structureEPOCCohort studyPulmonary and Respiratory Medicinemedicine.medical_specialty30-day mortalityRT-PCR real time reverse transcriptase-polymerase chain reactionSARS-CoV-2 severe acute respiratory syndrome coronavirus 2WHO World Health OrganizationMERS middle east respiratory syndrome03 medical and health sciencesInternal medicinemedicineCOPDCOVID-19 2019 novel coronavirusRisk factorIQR interquartile rangeLungmortalidad a 30 díasbusiness.industryFEV1 forced expiratory volume in one secondCOVID-19Retrospective cohort studymedicine.diseaseHR hazard ratioICS inhaled corticosteroidsCI confidence intervalCoronavirusCOPD chronic obstructive pulmonary disease030228 respiratory systemRespiratory failureILD interstitial lung diseaseMiddle East respiratory syndromeprognosisHFNC high flow nasal cannulabusiness
researchProduct

Measles in Italy: Viral strains and crossing borders

2019

In 2017, Italy experienced one of the largest outbreaks of measles in recent years, with 5404 notified cases and 4347 confirmed cases. A further 2029 cases were notified during the first 6 months of 2018, and 1516 of them were laboratory-confirmed. The B3 and D8 genotypes were identified as those responsible for the outbreak. Possible transmission routes can be established by monitoring the circulating measles virus strains in support of the national health authorities to warn people and travellers. Keywords: Outbreak, Measles, Genotype identification, Surveillance

0301 basic medicineGenotyping TechniquesWHO/EuropeSettore MED/42 - Igiene Generale E ApplicataDisease OutbreaksWHO0302 clinical medicineMeasleGenotype030212 general & internal medicineTravelSurveillancebiologyTransmission (medicine)General MedicineEmigration and ImmigrationInfectious DiseasesGenotype identificationItalyWorld Health Organization European RegionSequence AnalysisMicrobiology (medical)medicine.medical_specialtyGenotype030106 microbiologyWorld Health OrganizationMeasleslcsh:Infectious and parasitic diseasesEuropean Regional Verification Commission for Measles and Rubella Elimination; Genotype identification; MeaNS; Measles; Measles Nucleotide Surveillance; Outbreak; RVC; Surveillance; WHO; WHO/Europe; World Health Organization; World Health Organization European RegionOutbreak Measles Genotype identification SurveillanceMeasles virus03 medical and health sciencesGenotype identification; Measles; Outbreak; Surveillance; Emigration and Immigration; Genotype; Genotyping Techniques; Humans; Italy; Measles; Measles virus; Sequence Analysis DNA; Travel; Disease OutbreaksmedicineHumanslcsh:RC109-216Genotyping TechniquesMeaNSNational healthEuropean Regional Verification Commission for Measles and Rubella EliminationPublic healthOutbreakOutbreakSequence Analysis DNADNAmedicine.diseasebiology.organism_classificationVirologyRVCMeasles virusMeasles Nucleotide SurveillanceMeasles
researchProduct